Journals / Eurasian Journal of Pulmonology / 2020 / Cilt: 22 - Sayı: 1

Impairment in heart functions and prognostic role of N‑terminal pro‑brain natriuretic peptide in patients with chronic obstructive pulmonary disease exacerbation

Pages
48–54
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Multivariable logistic regression analysis showed that NT‑proBNP level was an independent predictor for the development of “event” (P < 0.001) and the cutoff point of it was found to be 303.5 pg/mL (0.639 sensitivity and 0.720 specificity).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: Chronic obstructive pulmonary disease (COPD) with comorbidities and cardiovascular disease is the most frequent one.
📊
Key Findings & Data:The primary outcome was development of “event” (readmission or rehospitalization or mortality) within 30 days.
💡
Conclusion & Impact:Multivariable logistic regression analysis showed that NT‑proBNP level was an independent predictor for the development of “event” (P < 0.001) and the cutoff point of it was found to be 303.5 pg/mL (0.639 sensitivity and 0.720 specificity).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) with comorbidities and cardiovascular disease is the most frequent one. The role of natriuretic peptides in determining prognosis of COPD exacerbations is not yet clear. The frequency of pathologic findings of transthoracic echocardiography (TTE) during COPD exacerbation showed wide variability. This study aims toevaluate the predictive role of N‑terminal pro‑brain natriuretic peptide (NT‑proBNP) in determining the short‑term prognosis of patients hospitalized with COPD exacerbation. As a secondary outcome, we aimed to investigate the frequency of TTE findings in these patients.MATERIALS AND METHODS: Eighty‑six consecutive patients with COPD exacerbation were included. NT‑proBNP levels were measured and TTE was carried out to whole of the participants at administration. The primary outcome was development of “event” (readmission or rehospitalization or mortality) within 30 days. The predictive role of NT‑proBNP level for the development of “event” was evaluated. As a secondary outcome of the study, the frequency of TTE findings was recorded.RESULTS: NT‑proBNP level of the patients who developed event within 30 days had significantly higher than who did not (2343.16 ± 4107.17 pg/mL vs. 843.22 ± 2349.96 pg/mL, P = 0.001). A high negative correlation was found between NT‑proBNP level and “time to event” (r = −0.992, P < 0.001). Multivariable logistic regression analysis showed that NT‑proBNP level was an independent predictor for the development of “event” (P < 0.001) and the cutoff point of it was found to be 303.5 pg/mL (0.639 sensitivity and 0.720 specificity). The most frequentechocardiographic findings were pulmonary hypertension (54.7%) and left ventricle diastolic dysfunction (39.5%).CONCLUSION: NT‑proBNP level is a strong predictor for short‑term prognosis of patients hospitalized with COPD exacerbation. Further and larger studies are needed to determine exact role of NT‑proBNP in long‑term prognosis of these patients.

🔖

Cite This Article

ATEŞ, C., AKPİNAR, S., HOŞGÜN, D., AKPİNAR, E. E. (2022). Impairment in heart functions and prognostic role of N‑terminal pro‑brain natriuretic peptide in patients with chronic obstructive pulmonary disease exacerbation. Eurasian Journal of Pulmonology, Cilt: 22 - Sayı: 1, 48–54. https://ajindex.com/articles/509626

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Berry CE, Wise RA. Mortality in COPD: Causes, risk factors, and prevention. COPD 2010;7:375‑82
  2. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thora×2010;65:930‑6
  3. Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: A mechanism for increased cardiovascular risk. Thora×2008;63:306‑11
  4. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009;4:337‑49
  5. Dickstein K, Cohen‑Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole‑Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933‑89
  6. Medina AM, Marteles MS, Sáiz EB, Martínez SS, Laiglesia FR, Rodríguez JA, et al. Prognostic utility of NT‑proBNP in acute exacerbations of chronic pulmonary diseases. Eur J Intern Med 2011;22:167‑71
  7. Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006;173:744‑50
  8. Gale CP, White JE, Hunter A, Owen J, Allen J, Watson J, et al. Predicting mortality and hospital admission in patients with COPD: Significance of NT pro‑BNP, clinical and echocardiographic assessment. J Cardiovasc Med (Hagerstown) 2011;12:613‑8
  9. Stolz D, Breidthardt T, Christ‑Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B‑type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088‑94
  10. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009;48:503‑12
  11. Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med 2016;194:1319‑36
  12. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, et al